SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConvaTec Regulatory News (CTEC)

Share Price Information for ConvaTec (CTEC)

Share Price is delayed by 15 minutes
Get Live Data
202.60    2.60 (1.30%)
Bid:
203.20
Ask:
203.60
Spread: 0.40 (0.197%)
Market Cap: £3.96b
CTEC Live PriceLast checked at - London Stock Exchange

Intraday ConvaTec Share Chart

CEO and CFO appointments

6 Nov 2025 07:00

RNS Number : 3877G
Convatec Group PLC
06 November 2025
 

 

 

Chief Executive Officer and Chief Financial Officer appointments

 

 

London, UK, 6 November 2025 - The Board of Directors of Convatec is pleased to announce the appointments of Jonny Mason as Chief Executive Officer and Fiona Ryder as Chief Financial Officer, with immediate effect.

 

Dr John McAdam, Chair of the Board of Directors, said:

"Since joining the business in 2022 as CFO, Jonny has demonstrated exceptional leadership and is highly regarded for his contribution to Convatec's successful turnaround. Jonny has extensive experience leading publicly listed and international businesses. The Board is confident in his ability to build on the successful transformation led by Karim over the last 6 years, and enable Convatec to deliver its full potential.

 

Fiona's appointment demonstrates the strength of internal talent that Convatec has built. She is a seasoned finance leader with a strong track record in global businesses, having led finance functions while based in the UK, US and Singapore. She has played a pivotal role in delivering Convatec's focus on simplification and productivity, has been fundamental to the success of the FISBE strategy.

 

I look forward to working with Jonny and Fiona to deliver value for all our stakeholders, making a real difference to the lives of people relying on Convatec's products, services and solutions."

 

Jonny Mason, Chief Executive Officer, said:

"Convatec is a brilliant business, full of talented colleagues, making a real difference to the lives of millions of people around the world. As we accelerate our growth and scale up the richest innovation pipeline in Convatec's history, we have significant potential ahead of us. Above all else, we will remain focused on delivering our vision, pioneering trusted medical solutions to improve the lives we touch. As my close colleague and friend Karim often said, Convatec's best days are ahead of us, and I'm determined to prove that he was right."

 

Fiona Ryder, Chief Financial Officer, said:

"I am very pleased for the opportunity to continue to build on what we have achieved through Convatec's turnaround and to support our teams to realise Convatec's full potential. The opportunities ahead of us are substantial. I'm looking forward to continuing to work with Jonny and the team to deliver our plans for the benefit of all our stakeholders."

 

Jonny Mason joined Convatec on 31 January 2022 as Chief Financial Officer and became a Director of the Company from 12 March 2022. He was appointed Interim CEO on 4 August 2025. Fiona Ryder joined Convatec on 3 January 2022 as Group Financial Controller and became Interim CFO on 4 August 2025. Fiona will become a Director of the Company from 6 November 2025.

 

Notes

There is no other information to be disclosed under UK Listing Rule 6.4.8 R in relation to the appointment of Fiona Ryder. 

 

Jonny Mason and Fiona Ryder will be paid in accordance with the Company's Directors' Remuneration Policy. Full details of Jonny Mason's and Fiona Ryder's remuneration arrangements will be disclosed in the Directors' Remuneration Report for 2025.

 

Contacts

Media: mediarelations@convatec.com

Analysts & investors: ir@convatec.com 

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPKPBNFBDDBDK
Date   Source Headline
3rd Aug 20177:02 amRNSDirectorate Change
3rd Aug 20177:00 amRNSConvaTec Group Plc First Half 2017 Results
1st Aug 201710:31 amRNSHolding(s) in Company
20th Jul 20177:00 amRNSConvaTec Acquisition of Woodbury Holdings
21st Jun 20177:00 amRNSDirectorate Change
16th Jun 20179:20 amRNSChange in External Directorships
13th Jun 20175:05 pmRNSHolding(s) in Company
12th Jun 20174:35 pmRNSHolding(s) in Company
9th Jun 201711:45 amRNSHolding(s) in Company
9th Jun 201711:41 amRNSHolding(s) in Company
9th Jun 20177:00 amRNSAnnouncement on Board of Directors
6th Jun 20177:00 amRNSResult of placing in ConvaTec Group Plc
5th Jun 20174:53 pmRNSProposed Placing in ConvaTec Group Plc
12th May 20177:00 amRNSSpecial Resolutions available at NSM
11th May 20172:22 pmRNSResults of AGM
4th May 20177:00 amRNSQ1 Trading Update ended 31 March 2017
2nd May 20177:00 amRNSLaunch of Flexi-Seal
5th Apr 20177:00 amRNSConvaTec Announces U.S. Launch of Foam Lite
4th Apr 20177:00 amRNSNotice of Annual General Meeting
3rd Apr 20173:00 pmRNSExecutive Committee
31st Mar 20175:22 pmRNSNotification of major interest in shares
31st Mar 20172:07 pmRNSNotification of major interest in shares
31st Mar 20171:49 pmRNSNotification of major interest in shares
30th Mar 20177:00 amRNSConvaTec expands partnership with Medtronic
29th Mar 20179:44 amRNSDirectorate Change
29th Mar 20177:00 amRNSConvaTec Group Plc Result of Placing
28th Mar 20175:54 pmRNSDirectorate Change
28th Mar 20174:55 pmRNSPlacing Launch and Sale Announcement
23rd Mar 20177:00 amRNSConvaTec Launches Sensi-Care®
21st Mar 20177:00 amRNS2016 Annual Report & Accounts
8th Mar 201712:00 pmRNSDirector/PDMR Shareholding
8th Mar 201712:00 pmRNSDirector/PDMR Shareholding
2nd Mar 20177:00 amRNSConvaTec full year 2016 results
27th Feb 20177:00 amRNSConvaTec Launches me+T recovery
22nd Feb 20177:00 amRNSConvaTec announces US GentleCath Glide launch
7th Feb 20177:00 amRNSNotice of Results
26th Jan 20177:00 amRNSLaunch of EsteemT+ Flex Convex 1-piece System
16th Jan 201712:13 pmRNSAppointment of Joint Corporate Brokers
4th Jan 20177:00 amRNSCONVATEC ANNOUNCES ACQUISITION OF EUROTEC
14th Dec 20161:59 pmRNSAnnouncement of margin loan
8th Dec 20161:00 pmRNSAnalyst Presentation
1st Dec 20167:00 amRNSHolding(s) in Company
1st Dec 20167:00 amRNSHolding(s) in Company
1st Dec 20167:00 amRNSHolding(s) in Company
1st Dec 20167:00 amRNSHolding(s) in Company
1st Dec 20167:00 amRNSTotal Voting Rights
15th Nov 20167:00 amRNSDirector/PDMR Shareholding
15th Nov 20167:00 amRNSDirector/PDMR Shareholding
14th Nov 20167:00 amRNSExercise of Over-allotment Option
8th Nov 20164:03 pmRNSNotification of major interest in shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.